YALE SCHOOL OF MEDICINE DEPARTMENT OF PATHOLOGY

For information about this site contact the webmaster

Yale Department of Pathology
PO Box 208023, LH108
New Haven CT, 06520-8023
203-785-2786

poster thumbnail

click to view larger pdf file

Fine Needle Aspiration Diagnosis of Mucinous Cystic Neoplasms and Intraductal Papillary Mucinous Neoplasms of the Pancreas: Cytomorphology, CEA Level and KRAS Mutation Status

Xiangbai Chen, M.D., Berrin Ustun, M.D., Jane Bernstein, M.D., Harry R. Aslanian, M.D., David Chhieng, M.D., Guoping Cai, M.D.

Departments of Pathology and Internal Medicine, Yale School of Medicine, New Haven, CT, USA

INTRODUCTION

Mucinous cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN) are the two most common mucinous lesions in the pancreas. Recognition of these mucinous lesions preoperatively is important due to their potential association with variable dysplasia and even invasive carcinoma. Since the patients with invasive MCNs are 5-10 years older than the patient with noninvasive MCNs, suggesting that progression from a noninvasive curable neoplasm to an invasive cancer occurs over a a period of years. Similar findings are also seen in the patients with IPMNs.
With advances in imaging techniques, more and more pancreatic lesions are identified. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) biopsy is becoming the choice of modality for diagnosing and classifying pancreatic lesions. However, accurate diagnosis of pancreatic lesions, especially cystic lesions, could be difficult based on cytomorphologic features alone due to low cellularity and overlapping cytomorphology. Previous studies have demonstrated that carcinoembryonic antigen (CEA) level analysis of cystic fluids could be helpful in differentiating mucinous from non-mucinous cysts. KRAS mutation has been implicated in pathogenesis of pancreatic neoplasms and KRAS mutation testing can improve diagnostic yield in cases with indeterminate cytological diagnoses.
In this retrospective study, we review the results of cytological diagnosis, CEA level and KRAS mutation status in MCNs and IPMNs diagnosed by histopathologic examination.

 

©2013 Yale Department of Pathology. All rights reserved.
Any redistribution or reproduction of part or all of the contents in any form is prohibited. You may not, except with express written permission of the author or the Department of Pathology, distribute or commercially exploit the content, nor may you transmit it or store it in any other website or other form of electronic retrieval system, including use for educational purposes.